Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - APPLIED DNA SCIENCES INCt1600453_ex99-1.htm
8-K/A - FORM 8-K (AMENDMENT NO. 1) - APPLIED DNA SCIENCES INCt1600453_8ka.htm

 

 

Exhibit 99.2

 

UNAUDITED PRO FORMA FINANCIAL INFORMATION

 

The following unaudited pro forma financial statements give effect to the Asset Purchase Agreement (the “Asset Purchase Agreement”), dated September 11, 2015, by and among Applied DNA Sciences, Inc. (the “Company” or “APDN”), Vandalia Research, Inc., a West Virginia corporation (now known as VR Holdings, Inc., “Vandalia”), and Derek A. Gregg, Vandalia’s Chief Executive Officer and a director of Vandalia, providing for the purchase by the Company of substantially all the assets of Vandalia (the “Asset Acquisition”) under the acquisition method of accounting in accordance with Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) Topic 805, Business Combinations (“ASC 805”), with the Company treated as the legal and accounting acquirer. The historical consolidated financial information has been adjusted in the unaudited pro forma financial statements to give effect to pro forma events that are (1) directly attributable to the Asset Acquisition, (2) factually supportable, and (3) with respect to the statements of operations, have a continuing impact on the combined results of the Company and Vandalia. The unaudited pro forma condensed combined balance sheet is based on the individual historical balance sheets of the Company and Vandalia as of June 30, 2015, and has been prepared to reflect the Asset Acquisition as if it occurred on June 30, 2015. The unaudited pro forma condensed combined statements of operations for the fiscal year ended September 30, 2014 and the nine months ended June 30, 2015 are based on the historical results of operations of the Company and Vandalia, giving effect to the Asset Acquisition as if it occurred on October 1, 2013. The fiscal year ended September 30, 2014 referenced in such unaudited pro forma statement of operations is the fiscal year of the Company. Because the fiscal year of Vandalia ends on December 31 of each year, such unaudited pro forma statement of operations makes reference to the fiscal year of Vandalia ended December 31, 2014.

 

The unaudited pro forma condensed combined financial information is presented for illustrative purposes only and is not necessarily indicative of: (i) results of operations and financial position that would have been achieved had the Asset Acquisition taken place on the dates indicated or (ii) the future results of operations or financial position of the Company following the Asset Acquisition. All pro forma adjustments and their underlying assumptions are described more fully in the notes to the unaudited pro forma condensed combined financial information. Actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.

 

 1  

 

 

CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Year Ended September 30, 2014

 

   Historical            
   APDN   Vandalia  

Total

Historical

  

Pro Forma
Adjustments

For The
Transaction

(Note 3)

  

Footnote

Reference

(Note 3)

 

Pro Forma

Combined

 
  

Year Ended

September 30,
2014

  

Year Ended

December 31,
2014

                
                        
Revenues  $2,721,224   $950,603    3,671,827   $(548,506)  A, D  $3,123,321 
Cost of goods sold   -    361,659    361,659    (142,461)   A   219,198 
Gross profit   2,721,224    588,944    3,310,168    (406,045)      2,904,123 
                             
Selling, general and administrative expenses   13,249,753    416,244    13,665,997    (146,596)   A, E   13,519,401 
Research and development   1,300,750    -    1,300,750    (275,653)   D   1,025,097 
Depreciation and amortization   442,262    14,546    456,808    89,624   A, B   546,432 
Total operating expenses   14,992,765    430,790    15,423,555    (332,625)      15,090,930 
(Loss) income from operations   (12,271,541)   158,154    (12,113,387)   (73,420)      (12,186,807)
Other income (expense):                            
Interest expense, net   (11,029)   (16,863)   (27,892)   16,863   A   (11,029)
Other income   123,914    -    123,914    -       123,914 
Loss on conversion of promissory notes   (908,005)   -    (908,005)   -       (908,005)
Loss before provision for  income taxes   (13,066,661)   141,291    (12,925,370)   (56,557)      (12,981,927)
Income taxes (benefit)   -    -    -    -       - 
Net (loss) income  $(13,066,661)  $141,291   $(12,925,370)  $(56,557)     $(12,981,927)
Income attributable to noncontrolling interest  $-   $2,133   $2,133   $(2,133)  A  $- 
Income attributable to Vandalia Research, Inc.  $-   $139,158   $139,158   $(139,158)  A  $- 
                             
Net loss per share - basic and diluted  $(0.97)  $-   $-   $-      $(0.96)
                             
Weighted-average shares outstanding -basic and diluted   13,515,518    -    -    -       13,515,518 

 

See accompanying notes to unaudited pro forma condensed combined financial information

 

 

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Nine Months Ended June 30, 2015

 

   Historical            
   APDN   Vandalia  

Total

Historical

  

Pro Forma
Adjustments

For The
Transaction

(Note 3)

  

Footnote

Reference

(Note 3)

 

Pro Forma

Combined

 
                        
Revenues  $5,028,234   $407,010   $5,435,244   $(203,083)  A  $5,232,161 
Cost of goods sold   -    353,762    353,762    (105,267)  A   248,495 
Gross profit   5,028,234    53,248    5,081,482    (97,816)      4,983,666 
                             
Selling, general and administrative expenses   11,078,405    288,907    11,367,312    (113,454)   A, F   11,253,858 
Research and development   961,745    -    961,745    -       961,745 
Depreciation and amortization   354,144    9,781    363,925    68,347   A, C   432,272 
Total operating expenses   12,394,294    298,688    12,692,982    (45,107)      12,647,875 
Loss from operations   (7,366,060)   (245,440)   (7,611,500)   (52,709)      (7,644,209)
Other income (expense)                            
Interest income (expense), net   (26,807)   (14,426)   (41,233)   14,426   A   (26,807)
Other income (expense)   (16,853)   (131)   (16,984)   131   A   (16,853)
Loss on conversion of promissory notes   (980,842)   -    (980,842)   -       (980,842)
Other income, net   (2,994,540)   -    (2,994,540)   -       (2,994,540)
Loss before provision for  income taxes   (11,385,102)   (259,997)   (11,645,099)   (38,152)      (11,683,251)
Income taxes (benefit)   -    (558,256)   (558,256)   558,256   G   - 
Net (loss) income  $(11,385,102)  $298,259   $(11,086,843)   (596,408)      (11,683,251)
Income (loss) attributable to noncontrolling interest   -    1,259    1,259    (1,259)  A   - 
Income (loss) attributable to Vandalia Research, Inc.  $-   $297,000   $297,000   $(297,000)  A  $- 
                             
Net loss per share - basic and diluted  $(0.63)  $-   $-   $-      $(0.65)
                             
Weighted-average shares outstanding -basic and diluted   18,075,506    -    -    -       18,075,506 

 

See accompanying notes to unaudited pro forma condensed combined financial information

 

 

 

 

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of June 30, 2015

 

   Historical   

            
  

APDN

  

Vandalia

   Total
Historical 
  

Pro Forma
Adjustments
For the
Transaction
(Note 4)

  

Footnote
Reference
(Note 4)

 

Pro Forma
Combined

 
                        
ASSETS                            
Current assets:                            
Cash and cash equivalents  $10,730,144   $25,934   $10,756,078   $(1,525,934)  A, B  $9,230,144 
Accounts receivable, net   2,077,756    184,518    2,262,274    (184 518 )   B   2,077,756 
Inventories   -    103,199    103,199    (73,199)  B   30,000 
Deferred tax asset   -    558,256    558,256    (558,256)  A, B   - 
Prepaid expenses and other current assets   209,831    2,727    212,558    (2,727)  A, B   209,831 
Total current assets   13,017,731    874,634    13,892,365    (2,344,634)      11,547,731 
Property, plant and equipment, net   526,816    38,663    565,479    (2,049)  A   563,430 
Other assets:                            
Deposits   52,988    10,000    62,988    -       62,988 
Goodwill   -    -    -    285,386   A   285,386 
Intangible assets, net   525,902    -    525,902    1,138,000   A   1,663,902 
Total assets  $14,123,437   $923,297   $15,046,734   $(923,297)     $14,123,437 
                             
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)                            
Current liabilities:                            
Accounts payable and accrued liabilities  $1,418,615   $291,596   $1,710,211   $(77,463)  B, C  $1,632,748 
Deferred revenue   204,863    -    204,863 1    -       204,863 
Lines of credit   -    157,908    157,908    (157,908)  B   - 
Current portion of related party term loan   -    2,859    2,859    (2,859)  B   - 
Total current liabilities   1,623,478    452,363    2,075,841(   (238,230)      1,837,611 
                             
Related party term loan, net of current portion   -    23,913    23,913    (23,913)  B   - 
Total liabilities   1,623,478    476,276    2,099,754    (262,143)      1,837,611 
                             
Shareholders’ equity:                            
Preferred stock   -    1,1,25    1,125    (1,125)  B   - 
Series A Preferred stock   -    -    -    -       - 
Series B Preferred stock   -    -    -    -       - 
Common stock   21,483    2,541    24,024    (2,541)  B   21,483 
Additional paid in capital   223,623,850    2,577,522    226,201,372    (2,577,522)  B   223,623,850 
Accumulated deficit   (211,145,374)   (2,261,572)   (213,406,946)   2,047,439   B, C   (211,359,507)
Noncontrolling interest   -    127,405    127,405    (127,405)  B   - 
Total shareholders’ equity (deficit) attritbutable to Applied DNA Sciences, Inc.   12,499,959    447,021    12,946,980    (661,154)      12,285,826 
Total liabilities and shareholders’ equity  $14,123,437   $923,297   $15,046,734   $(923,297)     $14,123,437 

 

See accompanying notes to unaudited pro forma condensed combined financial information

 

 

 

 

Notes to Unaudited Pro Forma Condensed Combined Financial Information

 

Note 1- Basis of presentation

 

The unaudited pro forma combined financial information herein is based upon the historical consolidated financial statements of APDN and Vandalia and has been prepared to illustrate the effects of the reported transactions in accordance with accounting principles generally accepted in the United States and pursuant to Article 11 of Regulation S-X.

 

The Asset Acquisition was accounted as a business combination using the acquisition method of accounting under the provisions of ASC 805, Business Combinations ("ASC 805"). Under ASC 805, all assets acquired are recorded at their acquisition date fair value. The allocation of the purchase price as reflected in the unaudited pro forma condensed combined financial data is based upon a third party valuation firm's valuation of the fair market value of assets acquired, as if the Asset Acquisition had occurred on June 30, 2015, with respect to the unaudited pro forma condensed combined balance sheet. With respect to the unaudited pro forma condensed combined statement of operations, the allocation of purchase price is reflected for the fiscal year ended September 30, 2014 and the nine months ended June 30, 2015, giving effect to the Asset Acquisition as if it occurred on October 1, 2013. The fiscal year ended September 30, 2014 referenced in such unaudited pro forma statement of operations is the fiscal year of the Company. Because the fiscal year of Vandalia ends on December 31 of each year, such unaudited pro forma statement of operations makes reference to the fiscal year of Vandalia ended December 31, 2014.

 

Note 2- Allocation of consideration transferred to the assets acquired

 

For the purposes of this pro forma financial information, fair values have been determined by a third party valuation firm for all assets acquired. The excess of the acquisition consideration over the fair value of the assets acquired is allocated to goodwill. The adjustments to reflect the acquisition method of accounting are based upon available information and certain assumptions which management believes are reasonable under the circumstances.

 

The following table summarizes the purchase price allocation as if the Asset Acquisition had occurred as of June 30, 2015:

 

Purchase price  $1,500,000 
      
Allocation of purchase price to the fair market values of assets acquired:     
Goodwill  $285,386 
Identifiable intangible assets   1,138,000 
Security deposit   10,000 
Fixed assets   36,614 
Inventory   30,000 
Total  $1,500,000 

 

The goodwill and identifiable intangible assets related to the Acquisition are tax deductible. 

 

 

 

 

Note 3- Pro Forma adjustments for the combined statement of operations

 

(A)Adjustment to remove items not purchased as part of the Asset Purchase Agreement. 

 

(B)Adjustment to record 12 months of identifiable intangible assets amortization of $91,966 and depreciation on fixed assets acquired of $12,204.

 

(C)Adjustment to record 9 months of identifiable intangible assets amortization of $68,975 and depreciation on fixed assets acquired of $9,153.

 

(D)Adjustment to eliminate sales of $275,653 between Vandalia and APDN during the fiscal year ended September 30, 2014.

 

(E)Adjustment to record 12 months of consulting expense per Derek Gregg's consulting agreement of $60,000 and remove his payroll expense of $101,175 for the same period.

 

(F)Adjustment to record 9 months of consulting expense per Derek Gregg's consulting agreement of $45,000 and remove his payroll expense of $78,558 for the same period.

 

(G)Adjustment to remove the deferred tax benefit for the gain on the sale of assets of $558,256.

 

Note 4- Pro Forma adjustments for the combined balance sheet

 

(A)Adjustment to record the purchase price consideration of $1,500,000 in cash.

 

(B)Adjustment to remove the items for not purchased as part of the Asset Purchase Agreement.

  

(C)Adjustment to accrue for transactions costs incurred as part of the Asset Purchase Agreement.